

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Helge H. RASMUSSEN, et al.

Serial No.: 10/594,160

Group No. 1613

Filed: May 24, 2007

Examiner: S. Townsley

For: METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYOCARDIAL
CONDITIONS

Attorney Docket No.: U 016502-0

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

We draw the attention of the Examiner to the attached references (first page only for U.S.
patent publications) which are also listed on the attached Form PTO-1449.

Respectfully submitted,

John Richards
c/o Ladas & Parry LLP
1040 Avenue of the Americas
New York, New York 10018-3738
Reg. No. 31053
Tel. No. (212) 708-1915

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

*(When using Express Mail, the Express Mail label number is mandatory;
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☐ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O.
Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. 1.8(a)

- ☐ with sufficient postage as first class mail.

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and
Trademark Office, to (571)-273-8300

Date: October 27, 2011

37 C.F.R. 1.10*

- ☐ as "Express Mail Post Office to Address"
Mailing Label No. _____ (mandatory)

EFS-WEB

- ☒ transmitted electronically

Signature

John Richards

(type or print name of person certifying)

FORM PTO-1449 U. S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			ATTY. DOCKET NO.	SERIAL NO.
			U 016502-0	10/594,160
			APPLICANT	
			Helge A. RASMUSSEN, et al.	
			FILING DATE	GROUP
			May 24, 2007	1613
U.S. PATENT DOCUMENTS				
Patent or Application		Name		Date
6,610,746		Synergistic effect of a sulfonylurea and/or non-sulfonylurea Kchannel blocker, and a phosphodiesterase 3 type inhibitor		31 January 2002
2003216294		Synergistic effect of a sulfonylurea and/or non-sulfonylurea Kchannel blocker, and a phosphodiesterase 3 type inhibitor		20 November 2003
5,977,154		Selective beta 3 adrenergic agonist		2 November 1999
FOREIGN PATENT DOCUMENTS				
Patent or Application Office/Number/Kind Code		Name		Date
EP	0 236 624	Substituted phenyl ethanol amines, processes for their preparation and pharmaceutical compositions containing them.		16 September 1987
EP	0 678 511	Thiazolidine and oxazolidine derivatives, their preparation and their medical use.		25 October 1995

FORM PTO-1449 U. S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	SERIAL NO.
	U 016502-0	10/594,160
	APPLICANT	
	Helge A. RASMUSSEN, et al.	
	FILING DATE	GROUP
	May 24, 2007	1613
NON-PATENT DOCUMENTS		
Articles		
*Hoang H. et al., "beta3-Adrenergic receptor activation decreases peripheral vascular resistance in heart failure by restoring endothelial dependant vasorelaxation via endothelial nitric oxide synthase upregulation", Journal of the American College of Cardiology, March, 3, 2004, Vol. 43 no. 5, p. 220A, No. 1144-133 (Abstract only)		
* Takahiro Horinouchi, et al., "B3-Adrenoceptor-mediated relaxation of guinea-pig gastric fundus smooth muscle: cAMP-independent characteristics and a primary role of 4-aminopyridine-sensitive voltage-dependent K ⁺ (K _v) channels", Folia Pharmacol. Jpn, Suppl 1, 109P-111P (2002) – (Full Japanese version, English abstract only)		
Horinouchi T and Koike K., "Functional identification of beta3-adrenoceptors in the guinea-pig ileum using the non-selective beta-adrenoceptor antagonist (+/-)-bupranolol.", J Auton Pharmacol., August 2000, Vol. 20, No. 4, pp. 253-258		
The Merck Manual, Japanese Version, December 10, 1999, 17th edition, pp. 1687-1707 (English version attached)		
Ridley JM et al., Inhibition of HERG K ⁺ current and prolongation of the guinea-pig ventricular action potential by 4-aminopyridine, J Physiol., June 15, 2003, Vol. 549, No. 3, pp. 667-672		
London B et al., Targeted replacement of KV1.5 in the mouse leads to loss of the 4-aminopyridine-sensitive component of I (K, slow) and resistance to drug-induced qt prolongation., Circ Res., May 11, 2001, Vol. 88, No. 9, pp. 940-946		
Lohse M. J. et al., "What is the role of β -Adrenergic Signaling in Heart Failure?" Circulation Research 14 Nov 2003 United States vol. 93, no. 10, 14 November 2003 (2003-11-14), pages 896-906, XP002458610, ISSN: 0009-7330		
Cheng Heng-Jie et al: "Functional significance of β 3-adrenergic receptor activation in heart failure", Journal of Molecular and Cellular Cardiology, vol. 33, no. 6, June 2001 (2001-06), page A20, XP002458611 & XVII Isht World Congress of the International Society for Heart Research; Winnipeg, Canada; July 06-11, 2001 ISSN: 0022-2828		
* Irmer, M. et al: "Treatment of severe congestive heart failure with the beta-agonist fenoterol", Klinische Wochenschrift, vol. 59, no. 12, 1981, pages 639-645, XP000924969 – (English abstract only)		
Sawa et al: "Recent Developments in the Design of Orally Bioavailable β 3-Adrenergic Receptor Agonists" Current Medicinal Chemistry 2006, pp. 25-37		
Rozec and Gauthier: " β 3-Adrenoceptors in the cardiovascular system: Putative roles in human pathologies", Pharmacology & Therapeutics 111 (2006) 652-673		
Brixius K., et al, "ENOS is not activated by nebivolol in human failing myocardium", Science Direct – Life Sciences 79 (2006) 1234-1241,		
White C.N., et al, "Activation of camp-dependent signaling induces oxidative modification of the cardiac Na ⁺ -K ⁺ pump and inhibits its activity" J Biol Chem. (2010); 285(18):13712-20.		

